S&P Futures
3,932.00 +34.25 (+0.88%) Dow Futures
31,420.00 +218.00 (+0.70%) Nasdaq Futures
12,038.00 +159.75 (+1.34%) Russell 2000 Futures
1,793.80 +18.90 (+1.06%) Crude Oil
111.65 -0.56 (-0.50%) Gold
1,842.80 +1.60 (+0.09%)
Freeline Therapeutics Holdings plc (FRLN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7500 |
| Open | 0.7400 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's Range | 0.7193 - 0.7699 |
| 52 Week Range | 0.6500 - 15.4000 |
| Volume | |
| Avg. Volume | 212,135 |
| Market Cap | 49.109M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FRLN
Related Research
- Freeline Therapeutics HoldingsDaily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic MoatyesterdayArgus Research
- GuruFocus.com
2 Net Current Asset Value Stocks to Consider
Short-term investors could be interested in these businesses
- GuruFocus.com
Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ...
Investment company Federated Hermes Prudent Bear Fund (Current Portfolio) buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, iShares MSCI Emerging Markets ETF, SPDR Biotech ETF, iShares MSCI EAFE ETF, sells S&P 500 ETF TRUST ETF, Financial Select Sector SPDR, Health Care Select Sector SPDR, ARK Genomic Revolution ETF, Cisco Systems Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Federated Hermes Prudent Bear Fund.
- Benzinga
Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 1/2 trial, saying the candidate proved durable in the second patient tested. Fabry disease is an inherited metabolic disorder resulting from the absent or markedly deficient activity of lysosomal enzyme α-galactosidase A, or α-Gal A. Patient Two was dosed at the lowest dose cohort of 7.5e11 vg/kg and experienced a sustained and durable response with an incr
